Dataset: PPARg and IL-4-induced gene expression data from PPARg +/- LysCre and PPARg fl/- LysCre mouse bone marrow-derived macrophages
Conditional macrophage-specific PPARg knockout mice were generated on C57Bl/6 background by breeding PPARg fl/- (one allele is floxed,...
Conditional macrophage-specific PPARg knockout mice were generated on C57Bl/6 background by breeding PPARg fl/- (one allele is floxed, the other is null) and lysozyme Cre transgenic mice. PPARg and IL-4 signaling was analyzed on bone marrow-derived macrophages. Bone marrow of 3 mice per group was isolated and differentiated to macrophages with M-CSF (20 ng/ml). 20 ng/ml IL-4 was used to induce alternative macrophage activation and 1 uM Rosiglitazone (RSG) was used to activate PPARg. From each mouse 4 samples were generated: 1. M-CSF, 2. M-CSF+RSG, 3. IL-4 and 4. IL-4+RSG. All compounds were added throughout the whole differentiation process, and fresh media was added every other day. Control cells were treated with vehicle (DMSO:ethanol). After 10 days, RNA was isolated and gene expression profiles were analyzed using Mouse Genome 430 2.0 microarrays from Affymetrix. 3 PPARg +/- LysCre and 3 PPARg fl/- LysCre mice were used to isolate bone marrow and from each macrophages were differentiated with or without IL-4 and simultaneously treated with vehicle or RSG. Altogether we analyzed 24 samples with 3 biological replicates as below.
- Species:
- mouse
- Samples:
- 24
- Source:
- E-GEOD-25123
- PubMed:
- 21093321
- Updated:
- Dec.12, 2014
- Registered:
- Nov.11, 2014
Sample | ACTIVATION | MOUSE | TREATMENT | VARIATION |
---|---|---|---|---|
GSM617163 | control | 1 | control | PPARg +/-LysCre |
GSM617164 | control | 1 | rosiglitazone | PPARg +/-LysCre |
GSM617165 | IL-4 | 1 | control | PPARg +/-LysCre |
GSM617166 | IL-4 | 1 | rosiglitazone | PPARg +/-LysCre |
GSM617167 | control | 2 | control | PPARg +/-LysCre |
GSM617168 | control | 2 | rosiglitazone | PPARg +/-LysCre |
GSM617169 | IL-4 | 2 | control | PPARg +/-LysCre |
GSM617170 | IL-4 | 2 | rosiglitazone | PPARg +/-LysCre |
GSM61717 | control | 3 | control | PPARg +/-LysCre |
GSM617172 | control | 3 | rosiglitazone | PPARg +/-LysCre |
GSM617173 | IL-4 | 3 | control | PPARg +/-LysCre |
GSM617174 | IL-4 | 3 | rosiglitazone | PPARg +/-LysCre |
GSM617175 | control | 4 | control | PPARg fl/-LysCre |
GSM617176 | control | 4 | rosiglitazone | PPARg fl/-LysCre |
GSM617177 | IL-4 | 4 | control | PPARg fl/-LysCre |
GSM617178 | IL-4 | 4 | rosiglitazone | PPARg fl/-LysCre |
GSM617179 | control | 5 | control | PPARg fl/-LysCre |
GSM617180 | control | 5 | rosiglitazone | PPARg fl/-LysCre |
GSM61718 | IL-4 | 5 | control | PPARg fl/-LysCre |
GSM617182 | IL-4 | 5 | rosiglitazone | PPARg fl/-LysCre |
GSM617183 | control | 6 | control | PPARg fl/-LysCre |
GSM617184 | control | 6 | rosiglitazone | PPARg fl/-LysCre |
GSM617185 | IL-4 | 6 | control | PPARg fl/-LysCre |
GSM617186 | IL-4 | 6 | rosiglitazone | PPARg fl/-LysCre |